CD44v6 has been causally associated with the development of metastases and with poor prognosis in various human malignancies. To elucidate the clinicopathological significance of CD44v6 expression in esophageal squamous cell carcinoma (ESCC), the present study aimed to investigate the expression of CD44v6 using immunohistological techniques. Using specific antibodies against CD44v6 and CD44s, expression of the proteins was analyzed immunohistochemically in 63 primary esophageal ESCCs, which were previously resected at the Nagoya City University Hospital without pre-operative induction therapy. Using light microscopy, the positive expression of CD44v6 was divided into a low- or high-expression group. The expression of CD44v6 in ESCC was analyzed with respect to various clinicopathological characteristics. The frequency of CD44v6 expression was 90.5% (57/63). The CD44v6 high-expression group comprised 55.6% of the patients (n=35) and the low expression group included 44.4% of the patients (n=28). In this study, no significant difference was observed between any clinicopathological factor and the immunohistochemical expression of CD44v6. In patients with high levels of CD44v6 expression, survival was markedly worse (p=0.0327). Favorable outcomes were observed for the clinicopathological characteristics of 6 patients whose tissue immunohistochemical expression of CD44v6 was not detected. Moreover, multivariate analysis confirmed that expression of CD44v6 was an independent prognostic indicator (risk ratio =2.793; p=0.0301). Overexpression of CD44v6 is a useful prognostic indicator of ESCC. Therefore, CD44v6 should be investigated as a potential target for therapy.
Esophageal squamous cell carcinoma (ESCC) is a malignant tumor belonging to the class of gastrointestinal carcinomas. Patients with ESCC have a poor prognosis despite intensive multimodality therapy such as surgery, radiation and chemotherapy. Almost 400,000 new cases of esophageal cancer are diagnosed annually worldwide, making it the eighth most common cancer and the sixth most common cause of cancer-related mortality (1). To improve patient survival, it is important to identify those relevant biomarkers in ESCC that are associated with adverse prognosis and to modify the therapeutic strategy for those patients accordingly. In the present study, expression of CD44v6 was assessed in the primary lesions of ESCC to elucidate its significance in clinical prognosis.
CD44 is a transmembrane glycoprotein involved in cell-cell and cell-extracellular matrix interactions, and whose role is to maintain cellular adhesion (2,3). CD44 is encoded by a single gene on chromosome 11p13, but actually represents a polymorphic group of transmembrane glycoproteins due to extensive alternative splicing and post-translational modifications (4). The human gene is composed of 20 exons, 10 of which (exons 1–5 and 16–20) are included in CD44 standard form (CD44s). CD44s is the smallest and most abundant member of this polymorphic and monogenic family of proteins. The remaining exons (exons 6–15) can be differentially inserted into the mature mRNA via alternative splicing and may give rise to hundreds of protein variants (5).
Overexpression of a number of CD44 variant isoforms was associated with tumor progression, suggesting that these CD44 isoforms have unique signaling properties (6–8). In colon cancer, CD44v3 was shown to promote invasion and resistance to apoptosis, while CD44v6 was associated with metastasis and decreased disease-free survival (6,7,9). In lung cancer, preferential CD44 variant expression occurs in squamous cell and bronchoalveolar carcinoma, where v5 and v6 variants appear to promote metastasis (8,10). Numerous reports showed that CD44 variants promote breast cancer progression, including the association of CD44v3-containing isoforms and breast cancer metastasis (6,11). The significance of CD44 variants in ESCC was discussed in previous investigations (2,12–14).
This study aimed to elucidate the clinicopathological significance of CD44v6 overexpression in ESCC.
Materials and methodsPatients and tissue samples
Samples were obtained from 63 patients with primary ESCCs. The patients had undergone radical esophagectomy without any pre-operative induction therapy at the Department of Surgery II, Nagoya City University Medical School, between 1997 and 2004. The study design was approved by the institutional review board of our university and written consent was obtained from all patients. Tumors were classified according to the guidelines for clinical and pathological studies on carcinoma of the esophagus established by the Japanese Society for Esophageal Diseases. Tissue specimens were collected from 51 males and 12 females, with a mean age of 63.5±8.3 years (range 46–78) (Table I). Tissues for immunohistochemistry were fixed in formalin and embedded in paraffin.
Immunohistochemistry
Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded ESCC tissues. Paraffin-embedded tumor sections were deparaffinized, rehydrated, heat-treated by microwaving in 10 mM citrate buffer for 15 min for antigen retrieval and cooled to room temperature. Sections were then treated with 0.3% H2O2 in methanol for 30 min to neutralize endogenous peroxidases, blocked with non-specific goat serum for 10 min and incubated with the primary monoclonal antibodies for CD44v6 (1:200; Serotec, UK) and CD44s (1:500; Enzo, Miami, FL, USA) overnight at 4°C. Immunoreactive protein was detected with a Dako Envision™ + System, HRP (DAB), and the sections were then counterstained with hematoxylin.
The immunostaining of CD44v6 and CD44s was subjectively assessed by two independent investigators (M.S. and H.I.) using light microscopy. The CD44v6-positive cells were counted and the positive expression was classified as: low-expression group with positive cells <50% and high-expression group with positive cells >50%.
Statistical analysis
Statistical analysis was performed using the Stat-View software package (Abacus Concepts, Berkeley, CA, USA). The Chi-square test was used to analyze the association between the immunohistochemical analysis and the clinical histopathological parameters of the patients. The survival of ESCC patients following surgery was assessed using the Kaplan-Meier method and survival times were compared using the log-rank test. The data are expressed as the mean ± SD. Multivariate analysis was performed using the Cox regression model and logistic multivariate regression model. In all analyses, p<0.05 was considered to be statistically significant.
Results
The frequency of CD44v6 expression was 90.5% (57/63). Representative cases of immunostaining are shown in Fig. 1. The CD44v6 high-expression group comprised 55.6% (n=35) of the patients and the low expression group included 44.4% of the patients (n=28). CD44v6 was observed only in epithelial and tumor cells. By contrast, CD44s was not solely expressed in epithelial and tumor cells in ESCCs. CD44s was also strongly present in lymphocytic cells and was loosely stained in the interstitium. Therefore, we could not evaluate the immunohistochemical expression for CD44s in the same manner. CD44v6 and CD44s staining was shown directly in consecutive serial sections of the same samples (Fig. 2).
The correlation between immunostaining for CD44v6 and the clinicopathological characteristics of the patients are shown in Table I. No significant correlation was observed between clinicopathological characteristics such as age, gender, T factor, N factor, stage, lymphatic invasion, venous invasion and differentiation, and the immunohistochemical expression of CD44v6 (Table I).
We subsequently investigated the correlation between immunostaining for CD44v6 and survival in ESCC patients after surgery (median follow-up, 28 months). The patients in the CD44v6 high-expression group had a significantly shorter survival following surgery than patients whose expression was low (p=0.0301, log-rank test) (Fig. 3). Moreover, favorable outcomes were noted for the clinicopathological characteristics of 6 patients whose expression of CD44v6 was not detected, (Table II).
Univariate analysis revealed that among the clinicopathological factors, tumor status [risk ratio (RR)=9.346; p=0.0025], lymph node status (RR=6.211; p=0.0001), lymphatic invasion (RR=6.623; p=0.0105), venous invasion (RR=2.809; p=0.0209) and CD44v6 expression (RR=2.491; p=0.0410) were all statistically significant prognostic factors (Table III).
Multivariate analysis revealed that CD44v6 overexpression (RR=2.793; p=0.0301) as well as tumor status (RR=9.259; p=0.0275) and lymph node status (RR=4.785; p=0.0023) were factors independently associated with an unfavorable prognosis of patients with ESCC (Table IV).
Discussion
The present study aimed to determine the clinicopathological significance of CD44v6 expression in ESCC. In this study, three main findings were noted. First, CD44v6 was expressed at a high frequency in patients with ESCC. Of the 63 ESCC cases, positivity for CD44v6 was observed in 57 cases (90.5%) (Table I). Second, the survival of patients whose expression of CD44v6 was high was significantly less favorable than that of patients whose expression was low (p=0.0301; Fig. 3). Third, immunohistochemical overexpression of CD44v6 was an independent prognostic indicator of patients with ESCC (Table III).
The first major finding involving CD44 in the metastatic process was the identification of a CD44 variant isoform containing exons v4-v7 in a highly metastasizing rat pancreatic carcinoma cell line (BSp73ASML). Transfection of this specific variant into related BSp73AS cells that did not metastasize conferred metastatic potential to those cells upon injection into syngeneic rats (15). Moreover, a CD44 exon v6-specific antibody blocked the metastatic propensity of these cells. When animals injected with metastatic BSpASv4-v7 cells were treated with anti-CD44v6 antibody, lymph node and lung metastases were blocked (16). Since these findings, CD44v6 has attracted increasing interest and investigations are currently underway regarding the physiological significance of CD44v6 as a prognostic factor for tumor progression. The exact role that CD44v6 plays in ESCC has yet to be elucidated, but has become an area of active study.
In previous studies, high expression frequencies exceeding 90% have been found in squamous cell carcinomas (SCCs) derived from head and neck, esophagus, skin and lung (10, 17–20). Our studies are in agreement with those results. In addition to CD44v6, CD44s was expressed in epithelial and tumor cells in ESCCs at high frequencies. CD44s stained strongly in lymphocytic cells and was loosely stained in the stroma. On the other hand, CD44v6 was expressed only in carcinoma and non-cancerous epithelial cells. Therefore, CD44v6 appears to be an ideal target antigen for the majority of SCCs. This frequent and homogeneous expression of CD44v6 renders SCC a suitable target for therapeutic approaches using CD44v6-specific antibodies.
There has been some controversy regarding the relationship of CD44v6 to the prognoses of various malignancies. It was previously reported that overexpression of CD44v6 is associated with metastasis of prostate cancer (21) and the prognosis of thymic epithelial neoplasms (22). In breast cancer, Kaufmann et al proposed that CD44v6 is a good marker for prognosis independent of progesterone receptor, lymph node status, tumor size and grade (23). By contrast, it has been suggested that CD44v6 is negatively associated with the progression of various malignancies. Lipponen et al studied 173 patients with bladder tumors and found that those with negative CD44v6 immunoreactivity had poorer prognoses (24). We showed the survival rates of ESCC patients with overexpression of CD44v6 to be markedly worse and that CD44v6 expression was a significant independent prognostic factor for patients with ESCC. Notably, in 6 patients lacking CD44v6 expression, favorable outcomes were found for their clinicopathological characteristics (Table II). These results suggest that ESCC patients lacking CD44v6 expression have more favorable prognoses, even when disease is advanced. CD44v6 is potentially a co-receptor for c-Met and VEGFR-2 (28,29). Further studies are required in order to clarify the role of CD44v6 protein in ESCC.
CD44v6 is a good prognostic marker and a suitable target for anticancer therapy for ESCC patients. Consequently, patients suffering from head and neck squamous cell carcinoma have entered phase I clinical trials utilizing CD44v6 antibodies that were either radiolabeled or covalently linked to a toxin (25,26). Although the phase I clinical trials appeared to be promising, 1 patient developed toxic epidermal necrolysis and succumbed to the disease. For this reason, the development of this drug has been terminated (27). Despite the termination of the trials, CD44v6 remains a valid target for anticancer therapy. Alternative strategies targeting CD44v6 functions have been presented.
In conclusion, overexpression of CD44v6 is an independent prognostic indicator for patients with ESCC. CD44v6 may be used as a prognostic marker for various malignancies, including ESCC. Although the precise molecular mechanism of up-regulated CD44v6 expression has yet to be clarified, our data have clearly indicated that CD44v6 may be a favorable candidate as a prognostic marker as well as a molecular target for the development of an effective therapeutic reagent for patients with esophageal cancer.
Acknowledgements
The authors would like to thank Ms. Shinobu Makino for the excellent technical assistance.
ReferencesParkinDMBrayFEvaluation of data quality in the cancer registry: principles and methods Part II. CompletenessEur J Cancer457567642009LyonsAJJonesJCell adhesion molecules, the extracellular matrix and oral squamous carcinomaInt J Oral Maxillofac Surg366716792007RautavaJSoukkaTInkiPLeimola-VirtanenRSaloniemiIHapponenRPHeikinheimoKCD44v6 in developing, dysplastic and malignant oral epitheliaOral Oncol393733792003NaorDWallach-DayanSBZahalkaMASionovRVInvolvement of CD44, a molecule with a thousand faces, in cancer disseminationSemin Cancer Biol182602672008Van WeeringDHBaasPDBosJLA PCR-based method for the analysis of human CD44 splice productsPCR Methods Appl31001061993IidaNBourguignonLYNew CD44 splice variants associated with human breast cancersJ Cell Physiol1621271331995KuniyasuHOueNTsutsumiMTaharaEYasuiWHeparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3Clin Cancer Res7406740722001PirinenRHirvikoskiPBohmJKellokoskiJMoisioKVirenMJohanssonRHollmenSKosmaVMReduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinomaHum Pathol31108810952000KuhnSKochMNubelTLadweinMAntolovicDKlingbeilPHildebrandDMoldenhauerGLangbeinLFrankeWWWeitzJZollerMA complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progressionMol Cancer Res55535672007Mizera-NyczakEDyszkiewiczWHeiderKHZeromskiJIsoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins in lung cancerTumour Biol2245532001IidaNBourguignonLYCoexpression of CD44 variant (v10/ex14) and CD44S in human mammary epithelial cells promotes tumorigenesisJ Cell Physiol1711521601997KoyamaSMaruyamaTAdachiSExpression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysisJ Cancer Res Clin Oncol12547541999GotodaTMatsumuraYKondoHOnoHKanamotoAKatoHWatanabeHTachimoriYNakanishiYKakizoeTExpression of CD44 variants and prognosis in oesophageal squamous cell carcinomaGut4614192000LiDMLiSSZhangYHZhangHJGaoDLWangYXExpression of human chorionic gonadotropin, CD44v6 and CD44v4/5 in esophageal squamous cell carcinomaWorld J Gastroenterol11740174042005GunthertUHofmannMRudyWReberSZollerMHaussmannIMatzkuSWenzelAPontaHHerrlichPA new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cellsCell6513241991SeiterSArchRReberSKomitowskiDHofmannMPontaHHerrlichPMatzkuSZollerMPrevention of tumor metastasis formation by anti-variant CD44J Exp Med1774434551993Van HalNLvan DongenGAStigter-van WalsumMSnowGBBrakenhoffRHCharacterization of CD44v6 isoforms in head-and-neck squamous-cell carcinomaInt J Cancer828378451999KankeMFujiiMKameyamaKKanzakiJTokumaruYImanishiYTomitaTMatsumuraYClinicopathological significance of expression of CD44 variants in head and neck squamous cell carcinomaJpn J Cancer Res914104152000HeiderKHSprollMSusaniSPatzeltEBeaumierPOstermannEAhornHAdolfGRCharacterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomasCancer Immunol Immunother432452531996SimonJCHeiderKHDietrichAWuttigCSchopfEAdolfGRPontaHHerrlichPExpression of CD44 isoforms in human skin cancerEur J Cancer32A139414001996EkiciSCerwinkaWHDuncanRGomezPCivantosFSolowayMSLokeshwarVBComparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancerInt J Cancer1121211292004SonobeSMiyamotoHNobukawaBIzumiHFutagawaTIshikawaNYamazakiAUekusaTAbeHSudaKPrognostic value of CD44 isoform expression in thymic epithelial neoplasmsCancer103201520222005KaufmannMHeiderKHSinnHPvon MinckwitzGPontaHHerrlichPCD44 variant exon epitopes in primary breast cancer and length of survivalLancet3456156191995LipponenPAaltomaSKosmaVMAla-OpasMEskelinenMExpression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-upJ Pathol1861571641998HeiderKHKuthanHStehleGMunzertGCD44v6: a target for antibody-based cancer therapyCancer Immunol Immunother535675792004StroomerJWRoosJCSprollMQuakJJHeiderKHWilhelmBJCastelijnsJAMeyerRKwakkelsteinMOSnowGBAdolfGRvan DongenGASafety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patientsClin Cancer Res6304630552000RiechelmannHSauterAGolzeWHanftGSchroenCHoermannKErhardtTGronauSPhase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinomaOral Oncol448238292008Orian-RousseauVChenLSleemanJPHerrlichPPontaHCD44 is required for two consecutive steps in HGF/c-Met signalingGenes Dev16307430862002TremmelMMatzkeAAlbrechtILaibAMOlakuVBallmer-HoferKChristoforiGHeroultMAugustinHGPontaHOrian-RousseauVA CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesisBlood114523652442009
Representative immunostaining of CD44v6 in ESCC. (A) Positive for CD44v6 expression. (B) Negative for CD44v6 expression (original magnification, ×100).
Comparative expression of CD44v6 and CD44s in ESCC. Carcinoma cells were positive for CD44v6 (A and C) and CD44s (B and D). CD44s was observed, not only in CD44s tumor cells, but also in lymphocytic cells and the interstitium (B and D). Cell nuclei were stained with hematoxylin (blue). Original magnification, ×100.
Overall survival rate of patients with ESCC according to CD44v6 immunostaining. Patients with overexpression of CD44v6 had a significantly shorter survival after surgery than patients with a low expression of CD44v6 (p=0.0327).
Relationship between the clinicopathological characteristics and immunostaining for CD44v6.
CD44v6 expression
Total
High (n=35)
Low (n=28)
p-value
Gender
Male
51
27
24
Female
12
8
4
0.3893
Age
<65
35
22
13
≥65
28
13
15
0.1922
T factor
T1
21
11
10
T2
10
5
5
T3
21
12
9
T4
11
7
4
0.9138
T1
21
11
10
T2–4
42
24
18
0.7199
N factor
Negative
20
10
10
Positive
43
25
18
0.5450
Stage
0
6
2
4
I
11
6
5
II
13
7
6
III
16
9
7
IV
17
11
6
0.7726
0–I
17
8
9
II–IV
46
27
19
0.4093
Lymphatic invasion
Negative
19
9
10
Positive
44
26
18
0.3901
Vein invasion
Negative
28
16
12
Positive
35
19
16
0.8206
Differentiation
Well
18
10
8
Moderate
40
24
16
Poor
5
1
4
0.2369
Clinicopathological characteristics of 6 patients.